概述

华氏巨球蛋白血症是一种罕见的癌症,最初始于白细胞。华氏巨球蛋白血症被认为是一种非霍奇金淋巴瘤,有时也称为淋巴浆细胞性淋巴瘤。

出现华氏巨球蛋白血症时,一些白细胞发生变化,变成癌细胞。癌细胞会在骨骼内产生血细胞的海绵状物质中积聚。这种海绵状物质称为骨髓。癌细胞会将健康的血细胞挤出骨髓。此外,癌细胞也可能在身体其他部位积聚,如淋巴结和脾脏。

这些癌细胞会产生一种蛋白质并在血液中积聚。过多的蛋白质会导致体内血流减慢,并引发其他问题。

症状

华氏巨球蛋白血症发展缓慢。可能多年都不引起症状。

但如果出现症状,则华氏巨球蛋白血症的症状可能包括:

  • 疲劳。
  • 发热。
  • 减重。
  • 盗汗。
  • 手脚麻木。
  • 淋巴结肿大。
  • 左侧肋下疼痛或饱胀感,这可能是由脾脏肿大引起的。
  • 容易瘀伤。
  • 鼻子或牙龈出血。
  • 头痛。
  • 气短。
  • 视力改变。
  • 意识模糊。

何时就医

如果出现任何令您担忧的持续症状,请与初级保健医生约诊。

病因

当细胞的 DNA 发生变化时,就有可能发展成癌症。细胞的 DNA 包含指示细胞进行哪些活动的指令。上述变化则指示细胞快速增殖。当健康细胞按照其自然生命周期正常死亡时,这些细胞会继续存活。

在华氏巨球蛋白血症中,这种变化发生在白细胞中。这种变化使一些白细胞变为癌细胞。导致这种变化的原因尚不明确。

癌细胞会在骨骼内产生血细胞的海绵状物质中积聚。这种海绵状物质称为骨髓。癌细胞会将健康的血细胞挤出骨髓。此外,癌细胞也可能在淋巴结和脾脏中积聚。

华氏巨球蛋白血症细胞会产生一种人体无法利用的蛋白质。这种蛋白质是免疫球蛋白 M,也称为 IgM。IgM 可在血液中积聚,从而导致体内血流减慢,并引发其他问题。

风险因素

增加患华氏巨球蛋白血症的风险因素包括:

  • 高龄。华氏巨球蛋白血症在任何年龄均可发病,但是最常见的发病年龄是 70 岁以上。
  • 男性。男性更易患华氏巨球蛋白血症。
  • 白人。与其他种族相比,白种人群更有可能患该病。
  • 有淋巴瘤家族史。有亲属患有华氏巨球蛋白血症或其他类型的 B 细胞淋巴瘤可能会增加您的患病风险。

并发症

Complications of Waldenstrom macroglobulinemia may include:

Hyperviscosity syndrome

Some people with Waldenstrom macroglobulinemia develop hyperviscosity syndrome. Hyperviscosity refers to the thickening of the blood that leads to slower flow through the blood vessels. In Waldenstrom macroglobulinemia, this happens because of the increased proteins in the blood. Hyperviscosity syndrome can cause life-threatening complications.

Bing-Neel syndrome

Bing-Neel syndrome describes when Waldenstrom macroglobulinemia involves the central nervous system. The central nervous system includes the brain and spinal cord. Bing-Neel syndrome can cause headaches, seizures, weakness or numbness in the limbs, and unusual nerve pain or tingling. Bing-Neel syndrome can develop when a person is in remission or, less commonly, when the cancer first starts. The outlook is usually worse when it develops later.

A switch to a more aggressive form of cancer

Some people with Waldenstrom macroglobulinemia can develop a more aggressive form of cancer.

Secondary cancers

People with Waldenstrom macroglobulinemia are at a higher risk of developing other cancers. These may include thyroid cancer, kidney cancer and melanoma.

Dec. 20, 2025

Living with 华氏巨球蛋白血症?

Connect with others like you for support and answers to your questions in the Blood Cancers & Disorders support group on Mayo Clinic Connect, a patient community.

Blood Cancers & Disorders Discussions

dtrgran59
What are my chances that MGUS turns into multiple myeloma?

39 Replies Wed, Jan 14, 2026

patientk
Anybody else have Factor V Leiden?

66 Replies Wed, Jan 14, 2026

See more discussions
  1. Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1475. Accessed Nov. 3, 2025.
  2. Epidemiology, pathogenesis, clinical manifestations, and diagnosis of Waldenstrom macroglobulinemia. https://www.uptodate.com/contents/search. Accessed Nov. 3, 2025.
  3. Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma. https://www.uptodate.com/contents/search. Accessed Nov. 3, 2025.
  4. Treatment and prognosis of Waldenstrom macroglobulinemia. https://www.uptodate.com/contents/search. Accessed Nov. 3, 2025.
  5. Elsevier Point of Care. Clinical Overview: Waldenstrom macroglobulinemia. https://www.clinicalkey.com. Accessed Nov. 3, 2025.
  6. Ferri FF. Waldenstrom macroglobulinemia. In: Ferri's Clinical Advisor 2026. Elsevier; 2026. https://www.clinicalkey.com. Accessed Nov. 3, 2025.
  7. Nimmagadda R. EPSi. Mayo Clinic. May 5, 2022.
  8. Elsevier Point of Care. Clinical Overview: Hyperviscosity syndrome. https://www.clinicalkey.com. Accessed Nov. 3, 2025.
  9. Prognosis in Waldenstrom's macroglobulinemia. International Waldenstrom's Macroglobulinemia Foundation. https://iwmf.com/prognosis. Accessed Nov. 13, 2025.